Italy Approves Betaglue’s Pancreatic Cancer Clinical Trial
BetaGlue Therapeutics has secured Italian Ministry of Health approval for a clinical investigation of YntraDose in unresectable locally advanced...
Phase 3 STELLAR Study Shows Improvements in Rare Brain Tumor
Median overall survival reached 34.9 months with eflornithine plus lomustine versus 23.5 months with lomustine alone in patients with...
FDA Approves Reduced Enrollment for Quelimmune Pediatric Study
Early real-world use of SeaStar Medical’s QUELIMMUNE in pediatric septic acute kidney injury has shown zero device-related adverse events...
New Nebokitug Phase 2 Results Published for Sclerosing Cholangitis
Nebokitug was safe and well tolerated through 48 weeks in primary sclerosing cholangitis, with a statistically significant reduction in...
BriaCell to Present Phase 2/3 Clinical & Survival Data
Topline: An interim pooled analysis from BriaCell’s ongoing pivotal Phase 3 in metastatic breast cancer reported an “excellent” safety...
New Study: Telehealth Is a Breakthrough for HIV Prevention
Nineteen percent of U.S. PrEP users received care through MISTR’s telehealth platform between 2018 and 2025, according to an...
A Breakthrough In Alcoholism Treatment: Clearmind Soars
Clearmind’s Phase I/IIa program for CMND-100 in alcohol use disorder has cleared an early safety gate: after dosing the...
Salarius, Texas Biomedical to Collaborate on Avian Flu Study
No clinical or in vitro efficacy data were reported. Decoy Therapeutics’ peptide conjugate influenza fusion inhibitors have only shown...
ORIC Pharma to Present Enozertinib Data in NSCLC at ESMO
ORIC will present Phase 1b data for enozertinib (ORIC-114), a selective, brain-penetrant EGFR/HER2 inhibitor, in previously treated HER2 exon...
Cognition Therapeutics Plans Phase 3 for Alzheimer’s Drug
In a Phase 2 subgroup of mild-to-moderate Alzheimer’s disease, zervimesine (CT1812) was associated with a 95% slowing of cognitive...